Navigation Links
Blood testing, mosquito style
Date:4/24/2009

A skin patch could one day provide a less-invasive alternative for diabetics who need to take regular samples of their own blood to keep glucose levels in check. The common method of drawing blood from fingertips and using glucose testing strips and metres can be painful, inconvenient and time-consuming.

Electrical engineers at the Schulich School of Engineering at the University of Calgary have patented a device called the Electronic Mosquito. The patch is approximately the size of a deck of cards and contains four micro-needles that "bite" sequentially at programmed intervals. The needles are electronically controlled to penetrate the skin deep enough to draw blood from a capillary, but not deep enough to hit a nerve. This means patients would experience little or no pain. The patch could be worn anywhere on the body where it could obtain accurate readings of capillary blood.

A sensor in each cell of the e-Mosquito measures sugar levels in the blood. This data can then be sent wirelessly to a remote device such a computer or a monitoring instrument worn on the wrist. The system could even be connected to an alarm to alert patients or doctors when blood sugar levels enter the danger zone.

"This is a dramatic improvement over manual poking, particularly for children and elderly patients," says Martin Mintchev, director of the Low Frequency Instrumentation Lab at the Schulich School of Engineering. "Our approach is radically different and offers a reliable, repeatable solution with the minor inconvenience of wearing something similar to an adhesive bandage."

Mintchev spent three years designing the e-Mosquito along with Karan Kaler, director of the Schulich School's Bio-Micro Electromechanical Systems (MEMS) Laboratory. Their next step is to make the components of the e-Mosquito smaller to fit more needles on the patch. Currently, there are four needles, so the patch would need to be changed at least once a day. Adding more needles would allow patients to wear the patch for longer periods of time or test their blood more frequently, even while they're asleep.

Eventually, Mintchev and Kaler hope to integrate a pump system so insulin injections can also become autonomous based on data from the e-Mosquito, thus converting the device into an external artificial pancreas.

"It's important to find an industry partner for this project," says David Reese, project manager with University Technologies International, the university's technology transfer, commercialization and incubation centre that works with U of C researchers to commercialize their technologies. "Industry has the resources and expertise to speed up the process of product development and bring this technology to market for the benefit of patients."

Diabetes has been described as a global epidemic. Approximately 246 million people around the world are affected by the disease. More than two million Canadians have diabetes, a number that is increasing because of the aging population and rising obesity rates, according to the Canadian Diabetes Association.

raw blood from a capillary, but not deep enough to hit a nerve. This means patients would experience little or no pain. The patch could be worn anywhere on the body where it could obtain accurate readings of capillary blood.

A sensor in each cell of the e-Mosquito measures sugar levels in the blood. This data can then be sent wirelessly to a remote device such a computer or a monitoring instrument worn on the wrist. The system could even be connected to an alarm to alert patients or doctors when blood sugar levels enter the danger zone.

"This is a dramatic improvement over manual poking, particularly for children and elderly patients," says Martin Mintchev, director of the Low Frequency Instrumentation Lab at the Schulich School of Engineering. "Our approach is radically different and offers a reliable, repeatable solution with the minor inconvenience of wearing something similar to an adhesive bandage."

Mintchev spent three years designing the e-Mosquito along with Karan Kaler, director of the Schulich School's Bio-Micro Electromechanical Systems (MEMS) Laboratory. Their next step is to make the components of the e-Mosquito smaller to fit more needles on the patch. Currently, there are four needles, so the patch would need to be changed at least once a day. Adding more needles would allow patients to wear the patch for longer periods of time or test their blood more frequently, even while they're asleep.

Eventually, Mintchev and Kaler hope to integrate a pump system so insulin injections can also become autonomous based on data from the e-Mosquito, thus converting the device into an external artificial pancreas.

"It's important to find an industry partner for this project," says David Reese, project manager with University Technologies International, the university's technology transfer, commercialization and incubation centre that works with U of C researchers to commercialize their technologies. "Industry has the resources and expertise to speed up the process of product development and bring this technology to market for the benefit of patients."

Diabetes has been described as a global epidemic. Approximately 246 million people around the world are affected by the disease. More than two million Canadians have diabetes, a number that is increasing because of the aging population and rising obesity rates, according to the Canadian Diabetes Association.


'/>"/>

Contact: Jennifer Sowa
jsowa@ucalgary.ca
403-220-3724
University of Calgary
Source:Eurekalert

Related biology news :

1. High blood pressure, low energy -- a recipe for heart failure
2. Right breakfast bread keeps blood sugar in check all day
3. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
4. Folic acid lowers blood arsenic levels, according to Mailman School of Public Health study
5. Folic acid lowers blood arsenic levels in Bangladesh
6. Study reveals a key to blood vessel growth and possible drug target
7. Expecting an afternoon nap can reduce blood pressure
8. MIT: blood may help us think
9. Immune cells promote blood vessel formation in mouse endometriosis
10. Elevated nitric oxide in blood is key to high altitude function for Tibetans
11. Fine-tuning lasers to destroy blood-borne diseases like AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... Paris Police Prefecture and ... ensure the safety of people and operations in several locations ... Teleste, an international technology group specialised in broadband ... its video security solution will be utilised by ... across the country. The system roll-out is scheduled for the ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: